Trade Breakfast Symposia

The below breakfast symposiums were available during the conference.

Wednesday 28th August, 7:00am - 8:30am

Abbott Diabetes Care
Glucose Meters with Built-In Automated Bolus Calculator: Gadget or Real Value for Insulin-Treated Diabetic Patients?
A practical review of the paper published in Diabetes Therapy 2013 by Ides M. Colin and Isabelle Paris, followed by discussion and sharing of case studies around the value of bolus calculators.
DO BGMs with a built-in bolus calculators improve the willingness and the ability of insulin-treated patients to make adequate therapeutic decisions and positively impact the metabolic control and the quality of life of users? Or are they simply a gimmick that will appeal to certain people with diabetes.
A panel of HCP’s involved in diabetes management will offer their perspectives and share case studies and experience.

Medtronic
Success in the next steps to prevent hypoglycaemia

Speaker: Clinical Professor Tim Jones

Dr Jones is Head of Department of Diabetes and Endocrinology, Princess Margaret Hospital for Children, Perth, Clinical Professor at the Institute for Child Health Research, University of Western Australia and holds an NHMRC Practitioner Fellowship.
This presentation includes a review of Low Glucose Suspend (LGS) integrated technology with new evidence showing the reduction of hypoglycaemia with sensor augmented pump therapy using automated insulin suspension. The clinical need to prevent hypoglycaemia will be emphasised given it is considered to be a major barrier to effective glycaemic control. Professor Jones will also discuss new Australian research on impaired hypoglycaemia awareness, as well as specific populations suitable for sensor augmented pump therapy with automated insulin suspension. Given ongoing research towards developing the closed loop ‘artificial pancreas’ system, the presentation will also focus on the progress to date including Predictive Low Glucose Management (PLGM) theory combined with case studies from the PiLGriM study showing PLGM therapy in action.

To register or for more information please
Email: australia.diabetes.event@medtronic.com
Phone: 1800 337 136 (toll free in Australia)
Visit: www.medtronic-diabetes.com.au

Topics covered:
Topic 1: Update and review on Low Glucose Suspend (LGS)
Topic 2: Hypo unawareness and specific indications
Topic 3: A focus on new developments in preventing hypoglycaemia

Thursday 29th August, 7:00am - 8:30am

Novo Nordisk
Patient and HCP attitudes and behaviours towards insulin therapy in Australia (GAPP2), and latest news on Novo Nordisk injectable therapies
An international cross-sectional survey (GAPP2), with a cohort in Australia, was conducted to increase the understanding of basal insulin-taking with an aim to investigate the frequency and impact of basal insulin dosing irregularities and hypoglycaemia in type 2 diabetes. The survey was conducted with both patients and physicians, and thus the difference in perceptions between the two groups was explored. The survey found a proportion of patients dosed their basal insulin irregularly which may warrant more frequent discussion with prescribers to address the behaviours and reasons behind this.
Novo Nordisk is constantly exploring opportunities to make their products more widely available to a larger number of patient groups. An update to the audience will be provided on the latest developments of Novo Nordisk’s injectable portfolio.

MSD
Diabetes, high risk sub-groups and the implications of hypoglycaemia
This session will increase awareness of diabetes high risk sub-groups, such as the elderly and those with renal impairment. The implications of hyperglycaemia and hypoglycaemia within these groups will be discussed and management options will be reviewed. As a result of attending this session attendees will enhance their skills in avoiding hypoglycaemia whilst still achieving good glycaemic control.

Confirmed speakers are:
Dr Ted Wu - Senior Staff Specialist in Endocrinology and Diabetes, Director of Health Professional Training, Royal Prince Alfred, Camperdown, NSW
Associate Professor Marg McGill AM - Manager, Diabetes Centre, Royal Prince Alfred Hospital, Camperdown, NSW

Sanofi
Addressing the preventable toll of chronic disease and premature death among people with a serious mental illness

Chairperson: Dr Roger Chen, Clinical Associate Professor, University of Sydney; Senior Staff Specialist, Endocrinology, Concord Repatriation General Hospital

Speaker: Kevin Humphries, NSW Minister for Mental Health, Minister for Healthy Lifestyles and Minister for Western NSW.

The Minister will discuss work being undertaken at a national level, commenced by a recent national summit formed to discuss the physical health of people with a mental illness and the high rates of chronic and preventable disease.
The summit was held in response to increasing concerns within the community and also growing evidence which shows that one in five Australians experience a mental health difficulty in any given year and the physical health of people living with a mental health difficulty is worse than those in the general community on just about every measure. Of particular focus is that people with a severe mental illness live between 10-32 years less than the general population. People with illnesses such as bipolar disorder or schizophrenia have heart-related problems, diabetes and obesity at much higher rates than the rest of the community.

AstraZeneca and Bristol-Myers Squibb Diabetes Alliance
Dapagliflozin clinical trials and in-clinic experience

Chair: A/Prof Sophia Zoungas
Speaker: A/Prof Jonathan Shaw
International Speaker: Prof Stephan Matthaei

The objective of this symposium is to provide attendees with a balanced overview of the dapagliflozin clinical trials program and to share the early in-clinic experience with dapagliflozin in Europe.

To register your attendance visit:
www.cievents.com/events/forxigasymposia

Friday 30th August, 7:30am - 9:00am

Novartis
Modern Approaches to Effective Glycaemic Control

The combination of metformin plus a sulfonyurea is broadly used for the treatment of type 2 diabetes. However, many patients on dual therapy still do not achieve glycaemic control. Adding a third oral agent can be an option for patients before initiating insulin therapy. The symposium will focus on the role of vildagliptin in this setting.

Nestlé Health Science
Managing obesity in Type 2 Diabetes – what are the options?

Obesity is a complex condition to manage, and is even more challenging for patients with diabetes, particularly those on medications including insulin. This presentation will provide an overview of the treatment options available and the relative merits of each. It will also provide some insights into the practicalities of managing diabetes medications while patients are on restricted eating plans.